Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials

Journal of Endovascular Therapy

Volumn 21, Issue 5, 2014, Pages 644-653

  Ohki, Takao ^a   Yokoi, Hiroyoshi ^b   Kichikawa, Kimihiko ^c   Kimura, Takeshi ^d   Snyder, Scott A ^e   Ragheb, Anthony O ^e   O'Leary, Erin E ^e   Jaff, Michael R ^f   Ansel, Gary M ^g   Dake, Michael D ^h  

^a JIKEI UNIVERSITY HOSPITAL   (Japan)

^b FUKUOKA SANNO HOSPITAL   (Japan)

^c NARA MEDICAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Med Institute Inc Lafayette   (United States)

^f VasCore   (United States)

^g RIVERSIDE METHODIST HOSPITAL   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Balloon angioplasty; Drug eluting stent; Ethnicity; Paclitaxel eluting stent; Peripheral artery disease; Peripheral vascular disease; Popliteal artery; Stenosis; Stent fracture; Superficial femoral artery

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; TICLOPIDINE; CARDIOVASCULAR AGENT;

AGED; AMPUTATION; ARTICLE; BARE METAL STENT; BODY MASS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEATH; DEVICE SAFETY; DRUG ELUTING CARDIOVASCULAR STENT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; JAPAN; JAPANESE (PEOPLE); LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT FRACTURE; TARGET LESION REVASCULARIZATION; VALIDITY; ADVERSE EFFECTS; CLINICAL TRIAL; DEVICES; DISEASE FREE SURVIVAL; DRUG ELUTING STENT; FEMORAL ARTERY; GERMANY; KAPLAN MEIER METHOD; LIMB SALVAGE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS; PROSTHESIS FAILURE; REPRODUCIBILITY; STENOSIS, OCCLUSION AND OBSTRUCTION; TIME; TREATMENT OUTCOME; UNITED STATES; VASCULAR PATENCY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; FEMORAL ARTERY; GERMANY; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LIMB SALVAGE; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; PROSTHESIS FAILURE; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASCULAR PATENCY;

EID: 84908144247     PISSN: 15266028     EISSN: 15451550     Source Type: Journal    
DOI: 10.1583/14-4753.1     Document Type: Article

References (27)

1. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxeleluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504.
2. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year followup from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61:2417-2427.
3. Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18:613-623.
4. Hiatt WR, Hirsch AT, Regensteiner JG, et al. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation. 1995;92:614-621.
5. Jaff M, Dake M, Pompa J, et al. Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices. Catheter Cardiovasc Interv. 2007;70:460-462.
6. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888.
7. Duda SH, Bosiers M, Lammer J, et al. Sirolimuseluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331-338.
8. Cejna M, Thurnher S, Illiasch H, et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23-31.
9. Cheng SW, Ting AC, Wong J. Endovascular stenting of superficial femoral artery stenosis and occlusions: results and risk factor analysis. Cardiovasc Surg. 2001;9:133-140.
10. Bosiers M, Deloose K, Callaert J, et al. Results of the Protege EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042-1050.
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351.
12. Nakagawa Y, Kimura T, Morimoto T, et al. Incidence and risk factors of late target lesion revascularization after sirolimus-eluting stent implantation (3-year follow-up of the j-Cypher Registry). Am J Cardiol. 2010;106:329-336.
13. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007;297:1992-2000.
14. Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006;113:1434-1441.
15. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
16. Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393-1402.
17. Machecourt J, Danchin N, Lablanche JM, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007;50:501-508.
18. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following offlabel use of drug-eluting stents. JAMA. 2007;297:2001-2009.
19. Park SJ, Kim YH. Current status of percutaneous coronary intervention with drug-eluting stents in Asia. Circulation. 2008;118:2730-2737.
20. Park KB, Do YS, Kim JH, et al. Stent placement for chronic iliac arterial occlusive disease: the results of 10 years experience in a single institution. Korean J Radiol. 2005;6:256-266.
21. Jaff MR, Katzen BT. Two-year clinical evaluation of the Zilver vascular stent for symptomatic iliac artery disease. J Vasc Interv Radiol. 2010;21:1489-1494.
22. Chong TJ, Rowe VL, Weaver FA, et al. Impact of race on infrainguinal angioplasty and stenting. Ann Vasc Surg. 2011;25:204-209.
23. Hu H, Zhang H, He Y, et al. Endovascular nitinol stenting for long occlusive disease of the superficial femoral artery in critical limb ischemia: a single-center, mid-term result. Ann Vasc Surg. 2011;25:210-216.
24. Ko YG, Kim JS, Choi DH, et al. Improved technical success and midterm patency with subintimal angioplasty compared to intraluminal angioplasty in long femoropopliteal occlusions. J Endovasc Ther. 2007;14:374-381.
25. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST). Circulation. 2007;116:285-292.
26. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16:261-269.
27. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.